🧬 The phase 2 HIMALAYA trial found no evidence that RIPK1 inhibition could slow functional decline in #ALS
📊 At week 24, ALSFRS-R change was −6.73 with SAR443820 vs −6.32 with placebo
Read 👉 www.neurologylive.com/view/ripk1-i...
#Neurology #ClinicalTrials #BrainHealth #Placebo #Neuro #Phase2
